Supernus Pharma Stock Price, News & Analysis

Supernus Pharmaceuticals (Nasdaq: SUPN) will present at the Jefferies Healthcare Conference on June 9, 2022, at 10:30 a.m. ET. CEO Jack Khattar will lead the presentation, highlighting the company’s focus on CNS diseases.

Investors can arrange meetings through the conference coordinator. The event occurs from June 8-10, 2022, at the New York Marriott Marquis. A live audio webcast will be available on the company's website, with a replay for 60 days post-conference. Supernus is known for its CNS product portfolio, including treatments for epilepsy, migraines, and Parkinson’s disease.

Supernus Pharmaceuticals reported first quarter 2022 revenues of $152.5 million, a 16% increase year-over-year. Net earnings rose to $25.6 million or $0.43 per diluted share. GAAP operating income stood at $2.0 million, while non-GAAP operating income was $28.0 million, reflecting an 11% increase from 2021. The FDA approved Qelbree® for adult ADHD treatment, contributing to 47,324 prescriptions in Q1, a 38% increase from Q4 2021. Financial guidance for 2022 remains $640 - $680 million in total revenues.

Supernus Pharmaceuticals (Nasdaq: SUPN) announced it will report Q1 2022 financial results after the market closes on May 9, 2022. President and CEO Jack Khattar and CFO Tim Dec will host a conference call at 4:30 p.m. ET to discuss the results, with a Q&A session following. A live webcast will be available on the Supernus website. The company specializes in developing CNS disease treatments, including products for epilepsy, migraine, and Parkinson’s disease.

Supernus Pharmaceuticals (Nasdaq: SUPN) announced FDA approval for Qelbree (viloxazine) to treat ADHD in adults, marking the first new nonstimulant treatment in 20 years. ADHD impacts 10 million adults in the U.S., with up to 90% of diagnosed children continuing into adulthood. The approval follows positive Phase III trial results, demonstrating significant symptom reduction compared to placebo (p=0.0040). Qelbree, a once-daily capsule, has shown a favorable safety profile, but may increase suicidal thoughts in some patients.

Supernus Pharmaceuticals (SUPN) filed its Annual Report on Form 10-K, revealing fourth-quarter and full-year results for 2021. Total revenues for Q4 were $159.1 million, with net product sales matching the revenue figure. However, combined R&D and SG&A expenses rose to $122.8 million, impacting operating earnings which dropped to $6.1 million from $43.0 million in Q4 2020. The full-year guidance for 2022 projects revenues between $640 million and $680 million and operating earnings of $20 million to $40 million, reflecting ongoing investment in R&D while addressing acquisition-related costs.

Supernus Pharmaceuticals (Nasdaq: SUPN) announced the upcoming filing of its Annual Report on Form 10-K for the fiscal year ending December 31, 2021. The company reaffirms its full-year 2022 financial guidance with anticipated total revenues between $640 million and $680 million, combined R&D and SG&A expenses of $460 million to $490 million, and operating earnings projected to be $20 million to $40 million. Additionally, a non-GAAP operating earnings estimate ranges from $130 million to $165 million.

Supernus Pharmaceuticals (Nasdaq: SUPN) announced a delayed filing of its Annual Report on Form 10-K for the fiscal year ending December 31, 2021, via Form 12b-25 on March 1, 2022. This delay puts the company out of compliance with Nasdaq Rule 5250(c)(1). However, Supernus expects to file the report by April 4, 2022, to regain compliance. The company specializes in developing treatments for central nervous system diseases, including epilepsy and ADHD, and is working on new treatments for various CNS disorders.

Supernus Pharmaceuticals (Nasdaq: SUPN) announced that President and CEO Jack Khattar will participate in a fireside chat at the Cowen 42nd Annual Health Care Conference on March 9, 2022, at 1:30 p.m. ET. The discussion will focus on the company's activities in developing products for central nervous system diseases.

Investors can access a live webcast of the presentation on the company's website, with an archived replay available for 60 days post-conference.

Supernus Pharmaceuticals (SUPN) announced preliminary 2021 revenues of $579.8 million, an 11% increase from 2020, driven by product sales growth and the acquisition of Adamas Pharmaceuticals. The company reported net product sales of $567.5 million, with Qelbree prescriptions reaching 34,328 in Q4 2021, marking a 122% increase from Q3 2021. SPN-830's NDA has been accepted with a PDUFA date set for October 2022. However, operating earnings are expected to decline significantly, and cash reserves decreased to approximately $458.8 million, down from $772.9 million in 2020.